This single center, single arm, open-label, phase I study will assess the safety of laparoscopically harvested autologous omentum, implanted into the resection cavity of recurrent glioblastoma multiforme (GBM) patients.
Subject is a male or female 18 years of age or older.
Subject is undergoing planned resection of known or suspected GBM.
Subject has a Karnofsky Performance Status (KPS) 70% or greater.
Subject has a life expectancy of at least 6 months, in the opinion of the Investigator.
Subject, if female, is pregnant or is breast feeding.
Subject intends to participate in another clinical trial.
Subject intends to undergo treatment with the Gliadel® wafer at the time of this surgery.
Subject has an active infection requiring treatment.